English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

.. Objectives: To analyze End of Treatment Response (ETR) and Sustained Virological Response (SVR) to HCV mono-infection in comparison with HCV/HBV co-infection. Study Design: Retrospective, multicenter study. Place and duration of study: The study was conducted at Department of Biochemistry and Molecular Biology, Army Medical College in collaboration with Armed Forces Institute of Pathology (AFIP), Rawalpindi and was completed in 12 months. Material and Methods: This study included two hundred and twelve HCV infected patients, treated with IFN-α-2b 6MU thrice weekly plus ribavirin 1000-1200 mg daily for 24 weeks duration. The subjects were divided into two groups of 152 HCV mono-infected and 60 HCV/HBV co-infected patients. Pretreatment biochemical factors, EVR and SVR were compared between two groups. Results: There is no significant difference between the proportions of HCV monoinfected versus HCV/HBV co-infected patients with ALT & AST levels before interferon therapy. The analysis by intention to treat exhibit EVR of 75% and 60% among co-infected and monoinfected patients respectively (p = 0.038). Similarly, SVR of 50% and 45% was observed in HCV/ HBV co-infected and mono-infected patients (p = 0.489). Conclusions: HCV/HBV co-infected and HCV mono-infected patients had similar biochemical characteristics with significant lower HCV-RNA titer in mono-infected patients. HCV/HBV co-infected patients showed higher EVR and SVR rates to interferon-alpha/ribavirin combination therapy as compare to mono-infected patients. The most possible factors responsible for favorable response rate in co-infected patients would be due to positive host immune reaction and reciprocal viral interaction.

COMPARISON OF HCV TREATMENT; HCV MONO-INFECTED AND HCV/HBV CO-INFECTED PATIENTS